Table 6 Baseline characteristics in the matched cohort post PSM analysis

Demographic data

Age (years)

65(55–74)

65(54–74)

65(56–73)

1.000

Male (n (%))

246(61.8)

120(60.3)

126(63.3)

0.606

BMI

28.2(24.4–32.5)

28.0(24.2–32.7)

28.4(24.5–32.5)

0.749

Vital signs

HR (/min)

80(67–96)

82(67–97)

79(66–96)

0.820

SBP (mmHg)

113(98–135)

112(98–133)

114(97–138)

0.750

DBP (mmHg)

63(54–73)

65(56–76)

62(53–72)

0.011

Temperature (℃)

36.4(34.0-37.2)

36.4(33.8–37.2)

36.6(34.1–37.3)

0.488

SpO2

99(95–100)

99(95–100)

99(96–100)

0.893

Comorbidities

MI (n (%))

83(20.9)

43(21.6)

40(20.1)

0.805

AF (n (%))

36(9.0)

18(9.0)

18(9.0)

1.000

CHF (n (%))

41(10.3)

18(9.0)

23(11.6)

0.510

CKD (n (%))

31(5.3)

11(5.5)

10(5.0)

1.000

ARF (n (%))

104(26.1)

50(25.1)

54(27.1)

0.732

Diabetes (n (%))

47(11.8)

24(12.1)

23(11.6)

1.000

Hypertension (n (%))

50(12.6)

25(12.6)

25(12.6)

1.000

Cardiogenic shock (n (%))

55(13.8)

28(14.1)

27(13.6)

1.000

Non-shockable rhythm

(n (%))

74(18.6)

34(17.1)

40(20.1)

0.520

Clinical indices

RBC (M/mcl)

4.0(3.3–4.5)

4.0(3.3–4.6)

3.9(3.3–4.4)

0.454

WBC (K/mcl)

13.9(10.0-19.3)

13(9.9–18.5)

14.2(10.1–20.0)

0.918

Platelet (K/mcl)

192(140–244)

190(141–256)

193(139–242)

0.272

HB (g/dL)

11.8(9.9–13.6)

11.9(10.0-13.9)

11.7(9.7–13.3)

0.414

Creatinine (mg/dL)

1.43(0.94–2.27)

1.34(0.92–2.28)

1.47(0.97–2.27)

0.725

BUN (mg/dL)

25.5(18.0–36.0)

25.0(17.0–36.0)

26.0(19.0–36.0)

0.735

FBG (mg/dL)

156.0(121.0-233.3)

140.0(115.0-179.0)

201.0(131.0-277.0)

< 0.001

Triglyceride (mg/dL)

109.0(81.0-151.0)

86.0(69.0-106.0)

146.0(112.0-208.0)

< 0.001

Tyg-index

9.20(8.80–9.61)

8.80(8.47–8.98)

9.60(9.35–10.08)

< 0.001

TC (mg/dL)

127.4(102.3-153.5)

133.8(108.0-161.0)

125.0(97.0-147.0)

0.093

HDL (mg/dL)

37.0(28.0–48.0)

37.0(29.0–47.0)

36.0(27.0–48.0)

0.319

LDL (mg/dL)

65.9(45.0-88.5)

68.0(47.0-92.8)

62.0(42.1–86.0)

0.140

Arterial pH

7.35(7.25–7.42)

7.35(7.26–7.41)

7.35(7.24–7.42)

0.868

PaCO₂ (mmHg)

40(33–47)

40(33–47)

40(34–46)

0.618

APS

88(66–111)

86(66–109)

89(64–115)

0.608

APACHE IV

100(76–125)

99(76–122)

102(75–127)

0.552

GCS

Verbal score

Motor score

Eyes score

3(3–10)

1(1–1)

1(1–5)

1(1–3)

4(3–10)

1(1–1)

1(1–5)

1(1–3)

3(3–10)

1(1–2)

1(1–5)

1(1–3)

0.542

0.774

0.321

0.416

Treatment measures

Bystander CPR (n (%))

145(36.4)

71(35.7)

74(37.2)

0.835

CPR>15 min (n (%))

44(11.1)

22(11.1)

22(11.1)

1.000

CPR<15 min (n (%))

102(25.6)

50(25.1)

52(26.1)

0.909

Unwitnessed status (n (%))

14(3.5)

9(4.5)

5(2.5)

0.415

Enteral nutrition (n (%))

0(0)

0(0)

0(0)

/

Amiodarone (n (%))

9(2.3)

6(3.0)

3(1.5)

0.503

Dobutamine (n (%))

7(1.8)

3(1.5)

4(2.0)

1.000

Dopamine (n (%))

51(12.8)

28(14.1)

23(11.6)

0.549

Epinephrine (n (%))

31(7.8)

16(8.0)

15(7.5)

1.000

Statin (n (%))

6(1.5)

4(2.0)

2(1.0)

0.685